Optimizing Outcomes with CFTR Modulator Therapy in the Management of Cystic Fibrosis: A Closer Look at
the Role of Combination Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2019 to January 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Vertex Pharmaceuticals

Description:
Cystic fibrosis (CF) is a genetic, autosomal recessive disorder that mainly affects the lungs but also the pancreas, liver, kidneys, and the intestines. Difficulty breathing and coughing up sputum as a result of frequent lung infections are characteristics of this disease. Other symptoms include sinus infections, poor growth, fatty stool, clubbing of the finger and toes, and infertility in males among others. Patients may have different degrees of symptoms due to several mutation classes in CF. According to the Cystic Fibrosis Foundation, about 30,000 people are currently living with CF and approximately 1,000 new cases are diagnosed each year. Although there is no cure for CF recent treatment breakthroughs have been able to reduce hospital admissions, enable easier breathing, provide a greater quality of life, and improve outcomes for patients. Fortunately for about half of CF patients, a new treatment is available for those who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease. This option is a major breakthrough in CF management as it is the first therapy that specifically targets an important genetic mutation.

Upon completion of this activity, participants will be able to:

  • Examine recently approved and emerging CFTR-based therapeutic options, including combination therapies, in terms of efficacy, safety, and clinical potential to optimize outcomes of patients with cystic fibrosis

  • Assess the role of newer combination CFTR modulator therapies and discuss ways to integrate them into the evolving treatment paradigm

  • Analyze the importance of newborn screening, accurate diagnosis, genomic evaluation, and early pharmacologic intervention in the management of cystic fibrosis

  • Explore best practices for improving patient adherence in the cystic fibrosis patient population

  • Identify cystic fibrosis patients who would potentially benefit from a CFTR modulator therapy
     

Faculty: Manu Jain, MD
Professor of Medicine and Pediatrics
Director of Adult CF
Northwestern University
m-jain@northwestern.edu

Disclosure:

Dr. Jain serves as a consultant for Gilead and Vertex. He serves on the speaker's bureau for Gilead and Vertex. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Vertex Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue